COMPANY PROFILE

Enhanc3D Genomics

Explore full profile

A spinout company from Babraham Institute

Milton, United KingdomFounded 2020Biotech & Life Sciences

Valuation $0–100M Latest valuation · 2022

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Enhanc3D Genomics

Enhanc3D Genomics is a functional genomics company focused on exploring the 3D organization of DNA to understand its impact on health and disease. The company operates in the biotechnology sector, serving pharmaceutical companies, research institutions, and healthcare providers. Its core product, the GenLink3D platform, integrates proprietary molecular biology technologies with machine learning to analyze genetic variations in non-coding regions of the genome. This platform helps identify how these variations influence disease progression, thereby aiding in the development of targeted therapies and precision medicine. Enhanc3D Genomics generates revenue through licensing its technology, offering genomic analysis services, and collaborating on research projects. The company is backed by investors such as Bioqube Ventures, Start Codon, BGF, Parkwalk, and private investors.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2020
Headquarters: Milton, United Kingdom
Employees: 9
Open positions: None listed
Dealroom signal: 58.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Precision Medicine, Spinout, AI Drug Discovery, Techbio, Hard Tech, Techbio Drug Discovery, Digital Pharma, DT and LS
Technology: 3D Technology
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Latest news

Press, funding announcements and product moves mentioning Enhanc3D Genomics.

See all news

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Sep 2025	—	—	Business Growth Fund · Meltwind · Parkwalk Advisors	↗
SERIES A✓Equity / VC	Oct 2022	$13M	$53M	Bioqube Ventures · Parkwalk Advisors · Business Growth Fund	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Enhanc3D Genomics website traffic

Latest recorded traffic for Enhanc3D Genomics is 1.3K monthly website visits, up 83.1% over the last three months. Enhanc3D Genomics's team declined 62.5% over the past year.

Latest monthly visits1.3K 3-month web change+83.1% 1-year team growth-62.5%

Monthly website visitsNov 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational	53	$47M	$160M
CYCytedUnique approach combines expertise in gastrointestinal oncology, digital pathology and AI-driven biomarker discovery	Cambridge, United Kingdom	Operational
MAMacomicsDeveloping precision medicines to modulate macrophages for the treatment of cancer	Edinburgh, United Kingdom	Operational
QTQuotient TherapeuticsDiscover how Quotient is pioneering a new field of genetics with somatic genomics to unveil a universe of genetic information and develop new therapies	Cambridge, United Kingdom	Operational
OLOutsee limitedDeveloping and applying innovative computational approaches to genomics for drug target discovery and precision medicine	Cambridge, United Kingdom	Operational
TBTailor BioTailor Bio is developing an AI-driven drug discovery platform for pan-cancer precision medicine by focusing on Chromosomal Instability	London, United Kingdom	Operational
CECellVoyantAn AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases	Bristol, United Kingdom	Operational
CACardiaTecApplying artificial intelligence on large-scale human multiomic data to develop the next generation of cardiovascular disease targets	Cambridge, United Kingdom	Operational